Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baupost Group Drops AVEO Pharmaceuticals Inc (AVEO) and Shifts Focus Towards Cheniere Energy (LNG)

Page 1 of 2

Seth Klarman’s Baupost Group shed its entire stake in AVEO Pharmaceuticals Inc (NASDAQ:AVEO), selling off more than 3.82 million Common Shares. Due to this recent transaction, the company has lost the backing of its largest institutional shareholder. On the same day, the hedge increased its holdings in Cheniere Energy Inc (NYSEMKT:LNG) by 13.6 million shares, or more than 120%. As disclosed in the 13G filing with the Securities and Exchange Commission, Baupost Group now owns around 24.8 million Common Shares, representing 10% of the company’s outstanding stock.


The employee-owned hedge fund Baupost Group, was founded in 1982 by Seth Klarman, a Harvard Business School graduate, and author of the book Margin of Safety. The fund’s equity portfolio, which is valued at around $5.7 billion, is made up primarily of companies active in the information technology sector, with the energy and healthcare industries ranking second and third respectively. By increasing its exposure to Cheniere Energy Inc (NYSEMKT:LNG) and shedding its position in AVEO Pharmaceuticals Inc (NASDAQ:AVEO), the hedge fund has made its preference for the energy sector quite clear. Due to the recent purchase of 13.6 shares of Cheniere Energy, Micron Technology Inc (NASDAQ:MU) has lost its spot as Baupost Group’s largest holding, despite accounting for 30% of the fund’s equity portfolio. Mr Klarman’s firm has been shifting its focus towards the energy and healthcare sectors for some time now, increasing its stakes in companies like PBF Energy Inc (NYSE:PBF) and Atara Biotherapeutics Inc (NASDAQ:ATRA).

AVEO Pharmaceuticals Inc (NASDAQ:AVEO) is a $45.5 million market cap biopharmaceutical firm, which focuses on discovering, developing, and commercializing targeted cancer therapies. Its AV-380 Program for example, is dedicated to finding ways to alleviate common complications in patients with advanced cancer, such as unintentional weight loss, progressive muscle wasting, and a loss of appetite. The company has a number of strategic partnerships with hospitals and other pharmaceutical companies, yet has been struggling to compete in this tough industry. Due to the sharp drop in shareholder value, AVEO has recently announced a corporate restructuring, which includes cutting its work-force and eliminating the firm’s internal research function. Considering the stocks grim outlook, it comes as little surprise that Mr. Klarman’s Baupost Group decided to eliminate this holding from its equity portfolio.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!